BRTX-100 Phase 2 Blinded Data Shows Significant Pain & Function Improvement; FDA Aligns on Phase 3
BRTX sits 56% above its 52-week low of $0.19.
Summary
BioRestorative Therapies announced positive blinded Phase 2 data for its lead candidate, BRTX-100, for chronic lumbar disc disease, demonstrating significant improvements in pain and function for over 50% of patients across multiple measures, with responses sustained for up to two years. Crucially, the company also reported alignment with the FDA on key elements for a potential Phase 3 clinical trial, including primary endpoints and development framework, with no safety concerns raised. This positive clinical update is highly material for the micro-cap biotech, especially following its recent 10-K filing which highlighted substantial doubt about its ability to continue as a going concern and a Nasdaq delisting notice. The strong data and FDA alignment provide a critical positive catalyst, potentially attracting future funding or partnerships. Investors will now watch for the planned unblinding of the full Phase 2 study and the initiation of Phase 3 trial activities.
At the time of this announcement, BRTX was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $0.19 to $2.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.